Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Condition:   Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients Intervention:   Drug: Surufatinib + envafolimab Sponsor:   Peking Union Medical College Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials